PURPOSE: Reirradiation (re-RT) of recurrent head and neck cancer (HNC) may achieve long-term disease control in some patients, at the expense of high rates of late sequelae. Limiting the re-RT targets to the recurrent gross tumor volume (rGTV) would reduce the volumes of reirradiated tissues; however, its effect on tumor recurrence pattern is unknown. METHODS AND MATERIALS: This is a retrospective review of 66 patients who underwent curative-intent re-RT for nonresectable recurrent or second primary mucosal squamous cell HNC. Treatment was delivered with three-dimensional conformal (3D) RT or intensity-modulated RT (IMRT). The targets in all patients consisted of the rGTVs with tight (0.5-cm) margins, with no intent to treat prophylactically lymph nodes or subclinical disease in the vicinity of the rGTVs. The sites of locoregional failures (LRFs) were determined using imaging at the time of failure and were compared with the rGTVs. RESULTS: Median re-RT dose was 68 Gy. Forty-seven patients (71%) received concomitant chemotherapy, and 31 (47%) received hyperfractionated, accelerated RT. At a median follow-up of 42 months, 16 (23%) were alive and disease-free. Fifty patients (77%) had a third recurrence or persistent disease, including 47 LRFs. All LRFs occurred within the rGTVs except for two (4%) (95% confidence interval, 0-11%). Nineteen patients (29%) had Grade > or = 3 late complications, mostly dysphagia (12 patients). CONCLUSIONS: Almost all LRFs occurred within the reirradiated rGTVs despite avoiding prophylactic RT of tissue at risk of subclinical disease. These results support confining the re-RT targets to the rGTVs to reduce reirradiated tissue volumes.
PURPOSE: Reirradiation (re-RT) of recurrent head and neck cancer (HNC) may achieve long-term disease control in some patients, at the expense of high rates of late sequelae. Limiting the re-RT targets to the recurrent gross tumor volume (rGTV) would reduce the volumes of reirradiated tissues; however, its effect on tumor recurrence pattern is unknown. METHODS AND MATERIALS: This is a retrospective review of 66 patients who underwent curative-intent re-RT for nonresectable recurrent or second primary mucosal squamous cell HNC. Treatment was delivered with three-dimensional conformal (3D) RT or intensity-modulated RT (IMRT). The targets in all patients consisted of the rGTVs with tight (0.5-cm) margins, with no intent to treat prophylactically lymph nodes or subclinical disease in the vicinity of the rGTVs. The sites of locoregional failures (LRFs) were determined using imaging at the time of failure and were compared with the rGTVs. RESULTS: Median re-RT dose was 68 Gy. Forty-seven patients (71%) received concomitant chemotherapy, and 31 (47%) received hyperfractionated, accelerated RT. At a median follow-up of 42 months, 16 (23%) were alive and disease-free. Fifty patients (77%) had a third recurrence or persistent disease, including 47 LRFs. All LRFs occurred within the rGTVs except for two (4%) (95% confidence interval, 0-11%). Nineteen patients (29%) had Grade > or = 3 late complications, mostly dysphagia (12 patients). CONCLUSIONS: Almost all LRFs occurred within the reirradiated rGTVs despite avoiding prophylactic RT of tissue at risk of subclinical disease. These results support confining the re-RT targets to the rGTVs to reduce reirradiated tissue volumes.
Authors: Aaron M Allen; Mohamed Elshaikh; Francis P Worden; Carol R Bradford; Theodoros N Teknos; Douglas B Chepeha; Christina Tsien; Laura A Dawson; Susan Urba; Gregory T Wolf; Daniel Normolle; Avraham Eisbruch Journal: Head Neck Date: 2007-02 Impact factor: 3.147
Authors: Joseph K Salama; Everett E Vokes; Steven J Chmura; Michael T Milano; Johnny Kao; Kirsten M Stenson; Mary Ellyn Witt; Daniel J Haraf Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-05 Impact factor: 7.038
Authors: David P Goldstein; Lucy Hynds Karnell; Min Yao; G Parker Chamberlin; Thanh X Nguyen; Gerry F Funk Journal: Head Neck Date: 2008-06 Impact factor: 3.147
Authors: Noel M Kramer; Eric M Horwitz; Jonathan Cheng; John A Ridge; Steven J Feigenberg; Roger B Cohen; Nicos Nicolaou; Eric J Sherman; James S Babb; Jason A Damsker; Corey J Langer Journal: Head Neck Date: 2005-05 Impact factor: 3.147
Authors: Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang Journal: Head Neck Date: 2008-03 Impact factor: 3.147
Authors: Matthew C Biagioli; Mark Harvey; Eloy Roman; Luis E Raez; Aaron H Wolfson; Subhakar Mutyala; Hyo S Han; Arnold Markoe Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-15 Impact factor: 7.038
Authors: Nicolien Kasperts; Ben J Slotman; C Rene Leemans; Remco de Bree; Patricia Doornaert; Johannes A Langendijk Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Erik P Sulman; David L Schwartz; Thuy T Le; K Kian Ang; William H Morrison; David I Rosenthal; Anesa Ahamad; Merril Kies; Bonnie Glisson; Randal Weber; Adam S Garden Journal: Int J Radiat Oncol Biol Phys Date: 2008-06-14 Impact factor: 7.038
Authors: Victor H F Lee; Dora L W Kwong; To-Wai Leung; Sherry C Y Ng; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze Journal: Eur Arch Otorhinolaryngol Date: 2016-10-13 Impact factor: 2.503
Authors: Felix Zwicker; Falk Roeder; Christian Thieke; Carmen Timke; Marc W Münter; Peter E Huber; Jürgen Debus Journal: Strahlenther Onkol Date: 2010-12-23 Impact factor: 3.621
Authors: E Pampana; R Gandini; M Stefanini; S Fabiano; A Chiaravalloti; D Morosetti; S Spano; G Simonetti Journal: Interv Neuroradiol Date: 2011-12-16 Impact factor: 1.610
Authors: Nadeem Riaz; Julian C Hong; Eric J Sherman; Luc Morris; Matthew Fury; Ian Ganly; Tony J C Wang; Weji Shi; Suzanne L Wolden; Andrew Jackson; Richard J Wong; Zhigang Zhang; Shyam D Rao; Nancy Y Lee Journal: Radiother Oncol Date: 2014-06-30 Impact factor: 6.280
Authors: Waqar Haque; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Milind Javle; Christopher R Garrett; Robert A Wolff; Prajnan Das Journal: Radiat Oncol Date: 2009-11-18 Impact factor: 3.481